Immune Design Corp. (NASDAQ:IMDZ) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.63) per share for the quarter.
Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. On average, analysts expect Immune Design Corp. to post $-2.27 EPS for the current fiscal year and $-2.34 EPS for the next fiscal year.
Immune Design Corp. (NASDAQ:IMDZ) traded up 12.20% during mid-day trading on Monday, hitting $4.60. 2,083,569 shares of the stock were exchanged. The stock’s market capitalization is $117.85 million. Immune Design Corp. has a 52 week low of $3.78 and a 52 week high of $13.05. The company has a 50-day moving average of $9.13 and a 200-day moving average of $8.49.
A number of equities analysts recently weighed in on IMDZ shares. Wells Fargo & Company lowered shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. ValuEngine lowered shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. Royal Bank Of Canada started coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. Finally, BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $14.75.
TRADEMARK VIOLATION WARNING: “Immune Design Corp. (IMDZ) Set to Announce Quarterly Earnings on Wednesday” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/30/immune-design-corp-imdz-set-to-announce-quarterly-earnings-on-wednesday.html.
In related news, Director Peter Svennilson bought 2,681,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Leo Guthart bought 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The shares were bought at an average price of $4.65 per share, with a total value of $279,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 2,786,000 shares of company stock valued at $11,535,500. 20.70% of the stock is owned by company insiders.
A hedge fund recently raised its stake in Immune Design Corp. stock. California State Teachers Retirement System grew its position in Immune Design Corp. (NASDAQ:IMDZ) by 8.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,174 shares of the biotechnology company’s stock after acquiring an additional 2,300 shares during the quarter. California State Teachers Retirement System owned about 0.12% of Immune Design Corp. worth $294,000 at the end of the most recent reporting period. Institutional investors own 51.44% of the company’s stock.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.